Login / Signup

Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma.

Yafan YangHaomiao LiXiankai ChenJianjun QinYong LiYaxing ShenRuixiang ZhangXiaozheng KangZhen WangQingfeng ZhengPeng LuoYin LiJie He
Published in: Thoracic cancer (2023)
It appears to be feasible to add immunotherapy to nabTP regimen for locally advanced ESCC. Compared with TP, nabTP plus ICIs can achieve a better pCR rate in ESCC.
Keyphrases
  • lymph node
  • locally advanced
  • squamous cell carcinoma
  • radiation therapy
  • tyrosine kinase
  • epidermal growth factor receptor